Health Care • Biotechnology: Pharmaceutical Preparations
$1.92 ▼ -0.08
(-4.00%)
MKT CAP: $66.7M • VOL: 196.8K
52W L $2 52W H $5
ROARABLE / RQD
D- • 39/100
PIOTROSKI
5 / 9
FBIO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $63.3M | $57.7M | $84.5M |
| YoY Revenue Growth % | +9.7% | -31.8% | — |
| Gross Profit | $42.3M | $36.8M | — |
| Gross Margin % | 66.9% | 63.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$70.2M | -$110.4M | -$142.3M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | $37.0M | $21.0M | $31.0M |
| EBITDA (Normalized) | — | -$110.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$65.8M | -$80.2M | -$128.2M |
| Capital Expenditures (CapEx) | — | $0 | — |
| Free Cash Flow (FCF) | -$65.8M | -$80.2M | -$128.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $79.4M | $57.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $49.9M | $22.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR FBIO.